Individual skill

tooluniverse-drug-target-validation

Quantitative drug-target validation pipeline. Scores druggability, selectivity, safety profile, ADMET feasibility, and structural tractability with a composite Target Validation Score (0-100) and GO/NO-GO recommendation. Use for go/no-go decisions on a target before commit-to-medchem, target prioritization across a list, and target-deselection rationale.

skills/tooluniverse-drug-target-validation/SKILL.md

Read pinned source

Source commit 5598a9fc97e32964fe9b703818e7d0747142f179

What was checked

Matches the observed repository HEAD
Yes
Scanner rules are current
No
Repository scan complete
No
Skill scan complete
No
Observed behavior
Not checked yet
Last checked
Nov 5, 2026

These are observations at the recorded commit, not a guarantee of safety. Review the source before running it.

Install this skill

Choose an agent in your Stack or copy a command below. Commands fetch the pinned commit and copy only this skill directory. Existing destinations are refused. Copying a command does not install anything.

An install command is unavailable: current rules, complete repository and skill scans, an eligible behavior level and a permitted license are required.

Repository context

Repository stars (not skill ratings)
1,778
Repository last updated
Nov 8, 2026
License
Apache-2.0

Observed agent integration: No specific integration evidence. Standard SKILL.md installation does not imply verified compatibility.

Files and excerpt

File metadata and permitted, redacted excerpts come from the recorded scan. Source links are pinned to that commit.

Browse files
Read excerpt

# Drug Target Validation Pipeline

Validate drug target hypotheses using multi-dimensional computational evidence before committing to wet-lab work. Produces a quantitative Target Validation Score (0-100) with priority tier classification and GO/NO-GO recommendation.

## Reasoning Before Searching

A valid drug target must pass 4 gates in order. Failing an early gate makes later gates irrelevant:

1. **Genetic evidence linking it to disease**: Does human genetic data (GWAS, rare variant studies, Mendelian genetics) support this target's role? Genetic evidence is the strongest predictor of clinical success. Use OpenTargets and GWAS catalog before anything else. If no genetic link exists, the hypothesis is speculative — document this clearly.
2. **Druggability**: Can a molecule reach and modulate the target? Check structure availability (PDB, AlphaFold), binding pocket prediction (ProteinsPlus), target class (kinase, GPCR, nuclear receptor = favorable; transcription factor, scaffold protein = difficult), and existing chemical probes.
3. **Safety — essentiality in normal tissue**: Is the target expressed in critical tissues (heart, liver, bone marrow)? Is knockout lethal in mice? High expression in essential tissue or lethality in mouse models is a strong safety red flag even before any clinical data.
4. **Competitive landscape**: Are other drugs already approved or in late-stage trials for this target? If so, the bar is differentiation, not first-in-class. Check ChEMBL, DrugBank, and ClinicalTrials.gov early.

Do not proceed to Phase 3 (Chemical Matter) before completing Phase 1 (Disease Association). Gate 1 failures should prompt a NO-GO or pivot recommendation.